chevron_leftBack
As of 24 April 2025, Shield Therapeutics plc has a market cap of $24.38M USD, ranking #28650 globally and #630 in the United Kingdom. It ranks #2868 in the Healthcare sector, and #606 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$24.38MUSD
18.38M GBP
Enterprise Value
$36.85MUSD
27.77M GBP
Revenue (TTM)
$22.54MUSD
16.99M GBP
EBITDA (TTM)
-$35.6MUSD
-26.83M GBP
Net Income (TTM)
-$37.97MUSD
-28.62M GBP
EBITDA Margin
-158%
Profit Margin
-168%
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Anders Lundstrom
open_in_new
Employees
73
Founded
2008
Website
shieldtherapeutics.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.1% | -9.4% | -23% | -0.8% | -48% | 68% |
Upcoming Earnings
Earnings Date
Fri, Apr 25
Tomorrow
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
STX
Shield Therapeutics PLC
ISIN: GB00BYV81293
Shares Out.:
Shares Outstanding:
1.042B1
Shares Float:
381.461M2
|
2 GBX | |
|
SHIEF
Shield Therapeutics PLC
ISIN: GB00BYV81293
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.0340 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Shield Therapeutics plc
Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
